title: Cost-effectiveness and implications of newborn screening for prolongation of QT interval for the prevention of sudden infant death syndrome.
abstract: OBJECTIVE
  To determine the cost-effectiveness of universal and high-risk neonatal electrocardiographic (ECG) screening for QT prolongation as a predictor of sudden infant death syndrome (SIDS) risk in a theoretical group of neonates.
  
  
  METHODS
  Incremental cost-effectiveness analysis with decision analytic modeling. A hypothetical cohort of healthy, term infants was modeled, comparing options of no screening, high-risk neonate screening, and universal screening. The high-risk strategy is speculative, because no currently accepted methodology is known for identifying infants at high risk for SIDS. Given the uncertain mechanisms of association between prolonged corrected QT interval (QTc) and SIDS, analyses were repeated under different assumptions. Sensitivity analyses were also performed on all input variables for both costs and effectiveness.
  
  
  RESULTS
  Under the assumption that neonatal electrocardiographic screening detects long QT syndrome responsive to conventional therapy, the cost-effectiveness of high-risk screening was $3403 per life year gained, whereas universal screening cost $18,465 per additional life year gained. However, if the effectiveness of SIDS therapy falls below 10%, the cost-effectiveness deteriorates to $28,376 per life year saved for the high-risk strategy and $118,900 for universal screening. The analyses were robust to a broad array of sensitivity analyses.
  
  
  CONCLUSIONS
  The acceptability of the cost-effectiveness of neonatal electrocardiographic screening is heavily dependent on the pathophysiologic mechanism of SIDS and on the efficacy of monitoring and antiarrhythmic treatment. The nature of this association must be elucidated before routine neonatal electrocardiographic screening is warranted.
authors.affiliation: Departments of Newborn Medicine, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, and Children's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Zupancic
authors.forename: J K
authors.initials: JK
authors.lastname: Triedman
authors.forename: M
authors.initials: M
authors.lastname: Alexander
authors.forename: E P
authors.initials: EP
authors.lastname: Walsh
authors.forename: D K
authors.initials: DK
authors.lastname: Richardson
authors.forename: C I
authors.initials: CI
authors.lastname: Berul
mesh_terms: D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data; D003661:Decision Support Techniques; D004562:Electrocardiography / Q000191:economics; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008133:Long QT Syndrome / Q000150:complications / Q000175:diagnosis / Q000191:economics*; D015997:Neonatal Screening / Q000191:economics*; D011379:Prognosis; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013398:Sudden Infant Death / Q000209:etiology / Q000517:prevention & control*; D014481:United States